世界中医药

目的：比较“三仁汤”联合布地奈德福莫特罗吸入剂和单用布地奈德福莫特罗吸入剂对“肥胖伴哮喘”表型患者的治疗效果，评价中药“三仁汤”汤剂联合哮喘吸入剂对“肥胖伴哮喘”表型的疗效。方法：本研究通过随机前瞻对照研究方法，将71例“肥胖伴哮喘”表型支气管哮喘患者随机分为观察组33例，对照组38例，观察组采用“三仁汤”汤剂联合布地奈德福莫特罗吸入剂治疗，对照组采用布地奈德福莫特罗吸入剂治疗。观察组服用“三仁汤”,1剂/d，200 mL/次，分2次口服，观察组及对照组中布地奈德福莫特罗均2次/d吸入，1吸/次（160 μg/4.5 μg），连续应用，于治疗4周后问卷调查［哮喘控制问卷（ACQ）评分、哮喘控制测试（ACT）评分］、肺功能检查，评估哮喘总体控制情况。结果：治疗4周后，观察组与对照组的ACT、ACQ症状评分及肺功能均优于治疗前，差异有统计学意义（P<0.05）。观察组与对照组的肺功能FEV1%预计值（P=0.45）、PEF%预计值（P=0.47）差异无统计学意义，但观察组的ACT（P=0.00）、ACQ（P=0.00）症状评分优于对照组，且观察组总体控制率（93.9%）优于对照组（86.8%），2组间差异有统计学意义（χ2=7.89，P=0.019）。结论：“三仁汤”汤剂联合布地奈德福莫特罗吸入剂在改善“肥胖伴哮喘”表型患者哮喘症状及哮喘总体控制率上明显优于单纯使用吸入剂。

English Summary:

To observe the therapeutic effect of Sanren decoction combined with budesonide formoterol inhalant and budesonide formoterol inhalant in the treatment of obese patients with asthma,then evaluate the efficacy of Sanren decoction combined with budesonide formoterol inhalant in obese patients with asthma.Methods:This was a prospective randomized control study in which 71 obese patients with asthma were randomly divided into observation group (n=33) and control group (n=38).Patients in the observation group were treated with Sanren decoction combined with budesonide formoterol inhalant,while patients in the control group were treated with budesonide formoterol inhalant.In the observation group,patients took one dose of Sanren per day,with 200 mL per time and twice orally.As for budesonide formoterol inhalant,it was inhaled twice a day,a suction once (160ug/4.5 μg) both in observation group and control group.After 4 weeks of treatment,questionnaires (asthma control questionnaire (ACQ) score,asthma control test (ACT) score) and pulmonary function tests were performed to assess overall control of asthma.Results:After 4 weeks of treatment,the scores of ACT and ACQ and pulmonary function in the observation group and the control group were significantly better than those before treatment (P<0.05).There was no significant difference between the observation group and the control group in FEV1% predicted (P=0.45) and PEF% predicted (P=0.45).However,the ACT score (P=0.00) and ACQ score (P=0.00) in observation group were better than those of the control group,and the overall control rate in observation group (93.9%) was better than that of the control group (86.8%) with significant statistical difference (χ2=7.89,P=0.019).Conclusion:The combination of Sanren decoction with budesonide formoterol inhalant has an advantage in improving asthma symptoms and overall control rate compared with using inhalants alone.

查看全文查看/发表评论下载PDF阅读器